BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Cost of Revenue

Cost of Revenue analysis for NAMS.

Quarterly Cost of Revenue

$500000.00

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$623000.00

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)